Create New Share
Please enter the email address below of the person you would like to share this article with.
An email will be sent to the recipient with a link to this chosen article.
A source for healthcare professionals to access the latest data and information on the diagnosis, treatment and management of patients with gut related disorders
Dr Fermín Mearin-Manrique
Director of the Department of Gastroenterology, Institute of Functional and Motor Digestive Disorders, Barcelona, Spain
The diagnosis of irritable bowel syndrome (IBS) should be based on the characteristic symptoms outlined in the Rome IV criteria; however, it does not eliminate the need to perform the relevant explorations to confirm the differential diagnosis from other pathologies that can manifest themselves in a similar fashion.1,2
The diagnosis of IBS with diarrhoea or functional diarrhoea gives a differential diagnosis from chronic diarrhoea.1,2 Causes of infection (especially Giardia lamblia), the consumption of drugs that may have diarrhoea as a side effect (eg. metformin, colchicine), poor absorption of some sugars (lactose, fructose, sorbitol), insufficient pancreatic exocrine function, intestinal bacteria overgrowth disorder, and diarrhoea due to bile acid malabsorption must also be considered.1,2 Coeliac inflammatory bowel disease, and microscopic colitis (lymphocytic colitis and collagenous colitis) should similarly be taken into account.3,4 Colon cancer can also present in a similar way, and the clinical suspicion or requirement for further diagnostic investigation depends on the patient’s age as well as the presence or absence of symptoms or warning signs.1
Job number: JB57410GBj Date of Preparation: June 2019
You must be registered to GutNews.org
to view or download these files
Brief report: length of ileal resection correlates with severity of bile acid malabsorption in Crohn’s disease
In patients with Crohn’s disease who had a prior surgical resection there was a modest correlation between the length of ileal resection and the severity of bile acid malabsorption (BAM), as defined by tauroselcholic (75selenium) acid (SeHCAT) retention values. Response to bile salt sequestrant therapy was not dependent on SeHCAT retention values.
Are you a healthcare professional?
This educational website is developed by GE Healthcare for educational purposes. The information contained within this website is intended for healthcare professionals. By entering this website you are confirming that you are a healthcare professional.
This link opens another website that is not under the review or control of GE Healthcare Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.